Figure S3 from Detection of MET Polysomy by Next-Generation Sequencing and Its Clinical Relevance for MET Inhibitors

Boyang Sun,Tian Qiu,Xiaoling Zeng,Jianchun Duan,Hua Bai,Jiachen Xu,Jin Li,Junling Li,Xuezhi Hao,Yutao Liu,Lin,Hongyu Wang,Xin Zhang,Jia Zhong,Jie Wang,Jianming Ying,Zhijie Wang

DOI: https://doi.org/10.1158/2767-9764.22546687

2023-01-01

Abstract:One MET-FISH-positive tumor was identified as negative by NGS

What problem does this paper attempt to address?

Figure S5 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors

Boyang Sun,Tian Qiu,Xiaoling Zeng,Jianchun Duan,Hua Bai,Jiachen Xu,Jin Li,Junling Li,Xuezhi Hao,Yutao Liu,Lin,Hongyu Wang,Xin Zhang,Jia Zhong,Jie Wang,Jianming Ying,Zhijie Wang

DOI: https://doi.org/10.1158/2767-9764.22546681.v1

2023-01-01

Abstract:One MET-FISH-negative patient was classified as having MET polysomy by NGS
Figure S2 from Detection of MET Polysomy by Next-Generation Sequencing and Its Clinical Relevance for MET Inhibitors

Boyang Sun,Tian Qiu,Xiaoling Zeng,Jianchun Duan,Hua Bai,Jiachen Xu,Jin Li,Junling Li,Xuezhi Hao,Yutao Liu,Lin,Hongyu Wang,Xin Zhang,Jia Zhong,Jie Wang,Jianming Ying,Zhijie Wang

DOI: https://doi.org/10.1158/2767-9764.22546690

2023-01-01

Abstract:The detection process using NGS of the study.
Figure S3 from Detection of met Polysomy by Next-generation Sequencing and Its Clinical Relevance for met Inhibitors

Boyang Sun,Tian Qiu,Xiaoling Zeng,Jianchun Duan,Hua Bai,Jiachen Xu,Jin Li,Junling Li,Xuezhi Hao,Yutao Liu,Lin,Hongyu Wang,Xin Zhang,Jia Zhong,Jie Wang,Jianming Ying,Zhijie Wang

DOI: https://doi.org/10.1158/2767-9764.22551561.v1

2023-01-01

Abstract:One MET-FISH-positive tumor was identified as negative by NGS
Figure S4 from Detection of met Polysomy by Next-generation Sequencing and Its Clinical Relevance for met Inhibitors

Boyang Sun,Tian Qiu,Xiaoling Zeng,Jianchun Duan,Hua Bai,Jiachen Xu,Jin Li,Junling Li,Xuezhi Hao,Yutao Liu,Lin,Hongyu Wang,Xin Zhang,Jia Zhong,Jie Wang,Jianming Ying,Zhijie Wang

DOI: https://doi.org/10.1158/2767-9764.22551558.v1

2023-01-01

Abstract:One MET-FISH polysomy tumor was classified as negative using the NGS assay.
Figure S1 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors

Boyang Sun,Tian Qiu,Xiaoling Zeng,Jianchun Duan,Hua Bai,Jiachen Xu,Jin Li,Junling Li,Xuezhi Hao,Yutao Liu,Lin Lin,Hongyu Wang,Xin Zhang,Jia Zhong,Jie Wang,Jianming Ying,Zhijie Wang

DOI: https://doi.org/10.1158/2767-9764.22551567

2023-01-01

Abstract:Flowchart of the study design
Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors.

Boyang Sun,Tian Qiu,Xiaoling Zeng,Jianchun Duan,Hua Bai,Jiachen Xu,Jin Li,Junling Li,Xuezhi Hao,Yutao Liu,Lin,Hongyu Wang,Xin Zhang,Jia Zhong,Jie Wang,Jianming Ying,Zhijie Wang

DOI: https://doi.org/10.1158/2767-9764.crc-22-0438

2023-01-01

Abstract:Next-generation sequencing (NGS) has failed to detect mesenchymal epithelial transition factor gene (MET) polysomy in previous studies. We included three non–small cell lung cancer (NSCLC) cohorts in this retrospective study to establish new criteria for detecting MET polysomy and to explore the clinical relevance of MET polysomy. Cohort 1 included 53 patients whose tissues were available for both FISH and NGS assays. Paired plasma and tissue samples were obtained from 261 patients with NSCLC as cohort 2. Cohort 3 included 46 patients with metastatic NSCLC, who presented with MET copy-number gain assessed by NGS. ROC analysis demonstrated that a cut-off point of 2.3 copies achieved the maximum Youden index in discriminating polysomy from normal copy number. Compared with the FISH test for MET polysomy, the sensitivity, specificity, and agreement of NGS were 90%, 90%, and 96.2%, respectively. Following optimization using maximum somatic allele frequency, the sensitivity and specificity of NGS for defining polysomy using plasma samples according to different circulating tumor DNA mutation frequencies were 42% and 63%. The concordance rate between tissue and plasma samples for detecting polysomy was 85%. Regarding the response to MET inhibitor, the median progression-free survival (PFS) of the MET amplification group was significantly higher than that of the polysomy group. The median PFS was similar between the polysomy and normal groups. Our results indicated that NGS may serve as an alternative method for detecting MET polysomy in NSCLC tissues. Moreover, patients with MET polysomy may not benefit from MET inhibitors. Significance: In this study, we established a methodology to differentiate polysomy from normal copy numbers and amplification using NGS. Moreover, this study suggests that it is critical to discriminate MET polysomy from amplification, for the former may dilute the clinical benefit of MET inhibitors.
Table TS1 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors

Boyang Sun,Tian Qiu,Xiaoling Zeng,Jianchun Duan,Hua Bai,Jiachen Xu,Jin Li,Junling Li,Xuezhi Hao,Yutao Liu,Lin,Hongyu Wang,Xin Zhang,Jia Zhong,Jie Wang,Jianming Ying,Zhijie Wang

DOI: https://doi.org/10.1158/2767-9764.22551552.v1

2023-01-01

Abstract:Clinicopathologic characteristics of patients in cohort 3.
Table TS2 from Detection of met Polysomy by Next-generation Sequencing and Its Clinical Relevance for met Inhibitors

Boyang Sun,Tian Qiu,Xiaoling Zeng,Jianchun Duan,Hua Bai,Jiachen Xu,Jin Li,Junling Li,Xuezhi Hao,Yutao Liu,Lin,Hongyu Wang,Xin Zhang,Jia Zhong,Jie Wang,Jianming Ying,Zhijie Wang

DOI: https://doi.org/10.1158/2767-9764.22551549.v1

2023-01-01

Abstract:Summary of MET status tested by NGS, MET inhibitors with clinical outcome and dynamic changes in gene alterations in cohort 3
Figure S2 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505091

2023-01-01

Abstract:Figure S2 shows the specificity of anti-MET VHH pool on MET in killing cancer cells.
Figure S3 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505088.v1

2023-01-01

Abstract:Figure S3 shows the efficacy of anti-MET VHH pool on tumor growth in individual mouse.
Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation

Chan Xiang,Xinze Lv,Ke Chen,Lianying Guo,Ruiying Zhao,Haohua Teng,Min Ye,Ting Kuang,Ting Hou,Chenglin Liu,Haiwei Du,Zhou Zhang,Yuchen Han

DOI: https://doi.org/10.1016/j.modpat.2024.100451

IF: 8.209

2024-02-01

Modern Pathology

Abstract:MET amplification (METamp) represents a promising therapeutic target in non-small cell lung cancer, but no consensus has been established to identify METamp-dependent tumors that could potentially benefit from MET inhibitors. In this study, an analysis of MET amplification/overexpression status was performed in a retrospectively recruited cohort comprising 231 patients with non-small cell lung cancer from Shanghai Chest Hospital (SCH cohort) using 3 methods: fluorescence in situ hybridization (FISH), hybrid capture-based next-generation sequencing, and immunohistochemistry for c-MET and phospho-MET. The SCH cohort included 130 cases known to be METamp positive by FISH and 101 negative controls. The clinical relevance of these approaches in predicting the efficacy of MET inhibitors was evaluated. Additionally, next-generation sequencing data from another 2 cohorts including 22,010 lung cancer cases were utilized to examine the biological characteristics of different METamp subtypes. Of the 231 cases, 145 showed MET amplification/overexpression using at least 1 method, whereas only half of them could be identified by all 3 methods. METamp can occur as focal amplification or polysomy. Our study revealed that the inconsistency between next-generation sequencing and FISH primarily occurred in the polysomy subtype. Further investigations indicated that compared with polysomy, focal amplification correlated with fewer co-occurring driver mutations, higher protein expressions of c-MET and phospho-MET, and higher incidence in acquired resistance than in de novo setting. Moreover, patients with focal amplification presented a more robust response to MET inhibitors compared with those with polysomy. Notably, a strong correlation was observed between focal amplification and programmed cell death ligand-1 expression, indicating potential therapeutic implications with combined MET inhibitor and immunotherapy for patients with both alterations. Our findings provide insights into the molecular complexity and clinical relevance of METamp in lung cancer, highlighting the role of MET focal amplification as an oncogenic driver and its feasibility as a primary biomarker to further investigate the clinical activity of MET inhibitors in future studies.

pathology
NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China

Qian Zheng,Xue Lin,Wenli Qi,Jun Yin,Juan Li,Ye Wang,Weiya Wang,Weimin Li,Zongan Liang

DOI: https://doi.org/10.1016/j.lungcan.2024.107897

IF: 6.081

2024-07-26

Lung Cancer

Abstract:Objectives Comprehensive data using Next-Generation Sequence (NGS) and fluorescence in situ hybridization (FISH) for detecting MET amplification is limited in Chinese patients, we evaluating NGS performance both in tissue and plasma samples using FISH as reference. We also sought to find optimal thresholds value for NGS in detecting MET amplification via bioinformatics methods. Method Patients progressed after 1st-, 2nd-, or 3rd-generation (G) EGFR-TKIs were enrolled. Tissue biopsy samples were performed for MET amplification detection via both NGS and FISH. Paired plasma samples were collected for MET amplification detection by NGS. The sensitivity, specificity and agreement were analyzed between NGS and FISH. Results 116 eligible patients were analyzed. 44 patients were male. 82 patients were after 3rd generation EGFR-TKI. MET amplification was detected in 43 (37.1 %) patients by FISH, including 19 (16.4 %) polysomy and 24 (20.7 %) focal amplification. The positive rate of MET amplification in post 3rd generation EGFR-TKI and post 1st/2ndgeneration EGFR-TKI resistant patients was 42.7 % (35/82), and 23.5 % (8/34). The sensitivity, specificity and agreement of detecting MET amplification by NGS in tissue were 39.5 % (17/43), 98.6 % (72/73) and 76.7 % (89/116), respectively, 66.7 % (16/24), 98.6 % (72/73) and 90.7 % (88/97) for focal MET amplification in tissue and 29.2 % (7/24), 94.5 % (69/73), 78.4 % (76/97) for focal amplification in plasma. Results were shown in the table below. Conclusion NGS is an alternative method for MET focal amplification detection in tissue. While the sensitivity of NGS testing in plasma needs further improvement to maximize identification of patients with potential benefit from dual-targeted therapy.

oncology,respiratory system
MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature

Pei Yuan,Xuemin Xue,Tian Qiu,Jianming Ying

DOI: https://doi.org/10.1177/17588359231221910

2024-01-01

Therapeutic Advances in Medical Oncology

Abstract:MET alterations, including MET exon 14 skipping variants, MET amplification, MET overexpression, and MET fusion, play pivotal roles in primary tumorigenesis and acquired resistance to targeted therapies, especially EGFR tyrosine kinase inhibitors. They represent important diagnostic, prognostic, and predictive biomarkers in many solid tumor types. However, the detection of MET alterations is challenging due to the complexity of MET alterations and the diversity of platform technologies. Therefore, techniques with high sensitivity, specificity, and reliable molecular detection accuracy are needed to overcome such hindrances and aid in biomarker-guided therapies. The current review emphasizes the role of MET alterations as oncogenic drivers in a variety of cancers and their involvement in the development of resistance to targeted therapies. Moreover, our review provides an overview of and recommendations on the selection of various cross-platform technologies for the detection of MET exon 14 skipping variants, MET amplification, MET overexpression, and MET fusion. Furthermore, challenges and hurdles underlying these common detection platforms are discussed.

oncology
Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study

Hui Xia,Junhua Zhang,Tong Chen,Mingzhao Wang,Dongna Chen,Tongguo Si,Yutao Liu

DOI: https://doi.org/10.1002/cam4.6047

IF: 4.711

2023-06-17

Cancer Medicine

Abstract:Purpose MET is a notable driver gene in the diversity of aberrations with clinical relevance, including exon 14 skipping, copy number gain, point mutations, and gene fusions. Compared with the former two, MET fusions are severely under‐reported, leaving a series of unanswered questions. In this study, we addressed this gap by characterizing MET fusions in a large, real‐world Chinese cancer population. Methods We retrospectively included patients with solid tumors who had DNA‐based genome profiles acquired through targeted sequencing from August 2015 to May 2021. MET fusion‐positive (MET+) patients were subsequently selected for clinical and molecular characterization. Results We screened 79,803 patients across 27 tumor types and detected 155 putative MET fusions from 122 patients, resulting in an overall prevalence of 0.15%. Lung cancer comprised the majority of MET+ patients (92, 75.4%). Prevalence was markedly higher in liver cancer, biliary tract cancer, and renal cancer (range 0.52%–0.60%). It was lower in ovarian cancer (0.06%). A substantial proportion (48/58, 82.8%) of unique partners were reported for the first time. High heterogeneity was observed for partners, with ST7, HLA‐DRB1, and KIF5B as the three most common partners. Mutational landscape analysis of lung adenocarcinoma (n = 32) revealed a high prevalence of TP53 in MET+ alterations, EGFR L858R, EGFR L861Q, and MET amplification. Conclusion To our knowledge, this is currently the largest study in characterizing MET fusions. Our findings warrant that further clinical validation and mechanistic study may translate into therapeutic avenues for MET+ cancer patients.

oncology
Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer.

Rachel Minne,Natalie Luo,Anne M. Traynor,Minxuan Huang,Luisina De Tullio,Jen Godden,Melissa Conrad Stoppler,Randall J. Kimple,Andrew Baschnagel

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.8553

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:8553 Background: In non-small cell lung cancer (NSCLC), the MET tyrosine kinase receptor can be dysregulated by mutations and/or gene amplification. The most common MET mutation is in exon 14 (METex14), leading to impaired receptor degradation and increased MET-mediated signaling causing sustained tumor proliferation. MET amplification also leads to continued MET signaling and oncogenesis and can be a mechanism of resistance to targeted therapy. We sought to compare the genomic landscape of METex14 and high-level MET amplified tumors, both of which can be targeted with tyrosine kinase inhibitors. Methods: We analyzed 18,047 NSCLC tumors (any stage/subtype) sequenced with Tempus xT assay (DNA-seq of 648 genes at 500x coverage, full transcriptome RNA-seq). Tumors were queried for METex14 mutations, high MET amplification (METamp), defined as copy number gain (CNG) ≥10, and other MET mutations (METother). Immuno-oncology (IO) biomarkers were compared across MET-altered and MET wild-type (METwt) groups. The prevalence of somatic gene alterations was compared similarly with the false-discovery rate (FDR) adjustment. Results: A total of 276 (1.53%) METex14, 138 (0.76%) METamp, 27 (0.15%) METother, and 17,606 (97.56%) METwt tumors were identified. Across groups, patients with METex14 were older, more likely to be female, and nonsmokers. METex14 exhibited the lowest tumor mutational burden (TMB) and lowest neoantigen tumor burden (NTB). PD-L1 positivity rates were higher in METex14 tumors compared to METamp and METwt tumors. MET log10 gene expression was highest in METamp. METamp exhibited the lowest proportion of CD4 T cells and the highest proportion of NK cells. Compared to METex14, METamp exhibited increased prevalence of TP53 (83% vs 37%), TFEC (46% vs 1.1%), CFTR (37% vs 1.4%), EGFR (31% vs. 7.6%), WNT2 (11% vs 0.4%), KEAP1 (14% vs 0.7%), and STK11 (8% vs 1.4%), and decreased prevalence of MDM2 (4.3% vs. 14%), and FRS2 (2.9% vs. 12%). Conclusions: In this large population-based analysis of MET-altered NSCLC, METex14 tumors exhibited differences in IO biomarkers and the somatic landscape compared to non-METex14 NSCLC tumors. Variations in immune profiles may affect immunotherapy selection in MET-altered NSCLC and require further exploration. [Table: see text]

oncology
Abstract 6499: The landscape of MET exon 14 skipping mutations in non-small cell lung cancer patients identified by next-generation sequencing

Chen Shi,Gao Ning,Zong Qinglan

DOI: https://doi.org/10.1158/1538-7445.am2024-6499

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Background: MET exon 14 skipping mutations (METex14) account for approximately 0.9%-4% in patients with non-small cell lung cancer (NSCLC). The primary detection methods are DNA and RNA-based next-generation sequencing (NGS). However, the effect of amplicon-based library construction (ALC) and capture-based library construction (CLC) on the detection characteristics of METex14 during the NGS process is not yet fully understood. Here we described the landscape of METex14 in NSCLC patients, as identified by NGS using two different library construction methods. Methods: A total of 6811 samples with NSCLC were enrolled in this study, including 3839 samples performed by DNA-based NGS with CLC, 64 samples performed by RNA-based NGS with CLC and 2908 samples performed by the synchronous DNA-based and RNA-based NGS with ALC. Only the pathogenic mutations and likely pathogenic mutations in clinical significance were rolled into our analysis. Results: The ranking of different methods, as determined by the positive rates for METex14, was RNA-based NGS with ALC (71/2908, 2.44%), RNA-based NGS with CLC (1/64, 1.56%), DNA-based NGS with CLC (54/3839, 1.41%) and DNA-based NGS with ALC (14/2908, 0.48%). Out of 2908 samples performed by the synchronous DNA-based and RNA-based NGS with ALC, 73 samples (2.51%) had METex14 detected at either the DNA or RNA level. METex14 were only detected at the RNA level in 59 patients, while they were only detected at the DNA level in 2 patients. This might be due to the limited probe design at DNA level and the Y1003 site which could not be detected at RNA level. As revealed by DNA-based NGS, the mutation forms causing METex14 include point mutations, indels, and large segment duplications. And the highest mutation rate is in the splice donor site (30.9%), the lowest is observed at position Y1003 (2.9%). Additionally, METex14 is more prevalent in patients over 60 years of age in Chinese NSCLC, with a statistically significant difference (P=0.0043). Conclusion: RNA-based detection of MET 14 skipping yielded a higher detection rate compared to DNA-based NGS, regardless of ALC or CLC. Combining DNA and RNA analysis is more suitable for detecting MET exon 14 skipping and increases the positive rate. Citation Format: Chen Shi, Gao Ning, Zong Qinglan. The landscape of MET exon 14 skipping mutations in non-small cell lung cancer patients identified by next-generation sequencing [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6499.

oncology
Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting

Xinghao Ai,Yongfeng Yu,Jun Zhao,Wang Sheng,Jing Bai,Zaiwen Fan,Xuemei Liu,Wenxiang Ji,Rongrong Chen,Shun Lu

DOI: https://doi.org/10.1177/17588359221112474

2022-01-01

Therapeutic Advances in Medical Oncology

Abstract:Background: Aberrant mesenchymal-epithelial transition/hepatocyte growth factor (MET/HGF) regulation presented in a wide variety of human cancers. MET exon 14 skipping, copy number gain (CNG), and kinase domain mutations/arrangements were associated with increased MET activity, and considered to be oncogenic drivers of non-small cell lung cancers (NSCLCs). Methods: We retrospectively analyzed 564 patients with MET alterations. MET alterations were classified into structural mutations or small mutations. MET CNG, exon 14 skipping, gain of function (GOF) mutations, and kinase domain rearrangement were defined as actionable mutations. Results: Six hundred thirty-two MET mutations were identified including 199 CNG, 117 exon 14 skipping, 12 GOF mutations, and 2 actionable fusions. Higher percentage of MET structural alterations (CNG + fusion) were detected in advanced NSCLC patients. Moreover, MET CNG was enriched while exon 14 skipping was rare in epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI)-treated advanced NSCLC patients. Ten of the 12 MET GOF mutations were also in EGFR-TKI-treated patients. Fifteen (68.1%) of the 22 patients treated with crizotinib or savolitinib had a partial response. Interestingly, one patient had a great response to savolitinib with a novel MET exon 14 skipping mutation identified after failure of immune-checkpoint inhibitor. Conclusions: Half of the MET alterations were actionable mutations. MET CNG, exon 14 skipping and GOF mutations had different distribution in different clinical scenario but all defined a molecular subgroup of NSCLCs for which MET inhibition was active.
A robust and accurate method to detect MET Exon 14–skipping mutation in pan-cancer samples using an NGS-based RNAseq approach.

Yongjie Wang,Ren HengDa,Yiqun Zhang,Zhihua Pei,Dongliang Wang,Qiming Zhou,Jing Wang

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e20575

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:e20575 Background: Met exon 14 skipping mutation(METex14) occurs in multiple cancer species, mainly in non-small cell lung cancer (NSCLC, 3~4%) and pulmonary sarcomatoid carcinoma (PSC, 22%). Several drugs expressed curative effect in previously treated patients who harboring METex14, such as savolitinib approved by NMPA, capmatinib and tepotinib licenced by FDA. Developing a quick and precise method which detect METex14 and help patients benefit from clinical drug treatment is a desiderative issue currently. Previous researches suggest that transcriptome-based RNA-seq method was superior to DNA-based NGS (exome, panel) and PCR method. Here We introduce a fast and accurate method to detect METex14 alternation in RNAseq data. Methods: We sequenced NGS-based Ribo-zero RNAseq (pair-end, 150bp×2) and METex14 ddPCR on 99 pan-cancer samples, of which 38 lung carcinoma (38%), 8 renal carcinoma (8%), 7 pancreatic carcinoma (7%). In 38 lung carcinoma, 35 NSCLC samples were consist by 29 lung adenocarcinoma (LUAD, 76%), 4 lung squamous carcinoma (LUSC, 10%) and 2 PSC (5%). Begin of the study, data quality control applied by Fastp and aligned to human hg19 genome by STAR subsequently. Next, MET exon14 related candidate soft-clipping reads were extracted from BAM files and translated to fastq file. Then we remapped the translated fastq file to hg19 genome with Blat using parameters ‘stepSize = 5, -repMatch = 2253, -minScore = 20, -minIdentity = 90’. Next, supporting reads were sequentially retained by: single end length longer than 18bp; block mapped reads of MET gene; the pair end reads mapped to genome if one end fall in the last 3bp of MET intron 13 and another end fall in at least initial 3bp of MET exon 15. Pair or single end support junction read, distance of junction site to reads end and site coverage were enrolled in a bayesian model to calculate METex14 confidence score (BMMETs). Threshold of our model was defined by the cut-point of max youden-index and 16 samples were validated METex14 by ddPCR. Finally, we would predict a sample with METex14 when score > = 0.752. Results: Our method reported 15 TP samples, 1 FP sample and 1 FN samples (AUC 0.97, sensitivity 0.88, specificity 0.98) while STAR-fusion detected 14 TR samples and 6 FP sample and 2 FN samples (AUC 0.715, sensitivity 0.64, specificity 0.73). BMMETs FP sample scored approximately 0.739 that close to the threshold. Conclusions: Strategy of screen reliable METex14 supporting reads and using bayesian model to calculate a METex14 confidence score could robustly and efficiently predict METex14 event in NGS-based RNAseq data.

oncology
Plasma ddPCR for the detection of MET amplification in advanced NSCLC patients: a comparative real-world study

Jun-Wei Su,Cheng-Di Weng,Xiao-Cheng Lin,Mei-Mei Fang,Xiao Xiao,Yi-Chen Zhang,Xu-Chao Zhang,Jian Su,Chong-Rui Xu,Hong-Hong Yan,Hua-Jun Chen,Yi-Long Wu,Jin-Ji Yang

DOI: https://doi.org/10.1177/17588359241229435

2024-01-01

Therapeutic Advances in Medical Oncology

Abstract:Background: Mesenchymal–epithelial transition ( MET) amplification is a crucial oncogenic driver and a resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) of non-small-cell lung cancer (NSCLC). Fluorescence in situ hybridization (FISH) is the gold standard for MET amplification detection. However, it is inapplicable when tissue samples are unavailable. Objective: This study assessed the performance of plasma droplet digital polymerase chain reaction (ddPCR) in MET amplification detection in NSCLC patients. Design and methods: A total of 87 NSCLC patients were enrolled, and 94 paired tissue and plasma samples were analyzed for the concordance between FISH and plasma ddPCR/tissue next-generation sequencing (NGS) in detecting MET amplification. In addition, the efficacy of patients with MET amplification using different detection methods who were treated with MET-TKIs was evaluated. Results: Plasma ddPCR showed substantial concordance with FISH (74.1% sensitivity, 92.5% specificity, and 87.2% accuracy with a kappa value of 0.68) and outperformed tissue NGS (kappa value of 0.64) in MET amplification detection. Combined plasma ddPCR and tissue NGS showed substantial concordance with FISH (92.3% sensitivity, 89.2% specificity, and an accuracy of 90.1% with a kappa value of 0.77). The efficacy is comparable in these NSCLC patients with MET amplification detected by FISH and plasma ddPCR who were treated with MET-TKIs. Conclusion: Plasma ddPCR is a potentially reliable method for detecting MET amplification in advanced NSCLC patients. Combined plasma ddPCR and tissue NGS might be an alternative or complementary method to MET amplification detection.

oncology
MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study

Xue-wen Liu,Xin-ru Chen,Yu-ming Rong,Ning Lyu,Chun-wei Xu,Fang Wang,Wen-yong Sun,San-gao Fang,Jing-ping Yuan,Hui-juan Wang,Wen-xian Wang,Wen-bin Huang,Jian-ping Xu,Zhen-ying Yue,Li-kun Chen

DOI: https://doi.org/10.1016/j.tranon.2020.100868

IF: 4.803

2020-12-01

Translational Oncology

Abstract:High frequency of MNNG HOS transforming (MET) exon 14 skipping mutation (MET exon 14Δ) has been reported in pulmonary sarcomatoid carcinomas (PSCs). However, the frequencies differ greatly. Our study aims to investigate the frequency of MET alterations and the correlations among MET exon 14Δ, amplification, and protein overexpression in a large cohort of PSCs. MET exon 14Δ, amplification, and protein overexpression were detected in 124 surgically resected PSCs by using Sanger sequencing, fluorescent in situ hybridization (FISH), and immunohistochemistry (IHC) respectively. MET exon 14Δ was identified in 9 (7.3%) of 124 cases, including 6 pleomorphic carcinomas, 2 spindle cell carcinomas and 1 carcinosarcoma. MET amplification and protein overexpression were detected in 6 PSCs (4.8%) and 25 PSCs (20.2%), respectively. MET amplification was significantly associated with overexpression (P < 0.001). However, MET exon 14Δ has no correlation with MET amplification (P = 0.370) and overexpression (P = 0.080). Multivariable analysis demonstrated that pathologic stage (hazard ratio [HR], 2.78; 95% confidence interval [CI], 1.28–6.01; P = 0.010) and MET amplification (HR, 4.71; 95% CI, 1.31–16.98; P = 0.018) were independent prognostic factors for poor median overall survival (mOS). MET alterations including MET exon 14Δ and amplification should be recommended as routine clinical testing in PSCs patients who may benefit from MET inhibitors. MET IHC appears to be an efficient screen tool for MET amplification in PSCs.

oncology

Figure S3 from Detection of MET Polysomy by Next-Generation Sequencing and Its Clinical Relevance for MET Inhibitors

Figure S5 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors

Figure S2 from Detection of MET Polysomy by Next-Generation Sequencing and Its Clinical Relevance for MET Inhibitors

Figure S3 from Detection of <i>met</i> Polysomy by Next-generation Sequencing and Its Clinical Relevance for <i>met</i> Inhibitors

Figure S4 from Detection of <i>met</i> Polysomy by Next-generation Sequencing and Its Clinical Relevance for <i>met</i> Inhibitors

Figure S1 from Detection of <i>MET</i> Polysomy by Next-generation Sequencing and Its Clinical Relevance for <i>MET</i> Inhibitors

Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors.

Table TS1 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors

Table TS2 from Detection of <i>met</i> Polysomy by Next-generation Sequencing and Its Clinical Relevance for <i>met</i> Inhibitors

Figure S2 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Figure S3 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation

NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China

MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature

Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study

Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer.

Abstract 6499: The landscape of MET exon 14 skipping mutations in non-small cell lung cancer patients identified by next-generation sequencing

Comprehensive analysis of <i>MET</i> mutations in NSCLC patients in a real-world setting

A robust and accurate method to detect MET Exon 14–skipping mutation in pan-cancer samples using an NGS-based RNAseq approach.

Plasma ddPCR for the detection of MET amplification in advanced NSCLC patients: a comparative real-world study

MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study

Figure S3 from Detection of MET Polysomy by Next-Generation Sequencing and Its Clinical Relevance for MET Inhibitors

Figure S5 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors

Figure S2 from Detection of MET Polysomy by Next-Generation Sequencing and Its Clinical Relevance for MET Inhibitors

Figure S3 from Detection of &lt;i&gt;met&lt;/i&gt; Polysomy by Next-generation Sequencing and Its Clinical Relevance for &lt;i&gt;met&lt;/i&gt; Inhibitors

Figure S4 from Detection of &lt;i&gt;met&lt;/i&gt; Polysomy by Next-generation Sequencing and Its Clinical Relevance for &lt;i&gt;met&lt;/i&gt; Inhibitors

Figure S1 from Detection of <i>MET</i> Polysomy by Next-generation Sequencing and Its Clinical Relevance for <i>MET</i> Inhibitors

Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors.

Table TS1 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors

Table TS2 from Detection of &lt;i&gt;met&lt;/i&gt; Polysomy by Next-generation Sequencing and Its Clinical Relevance for &lt;i&gt;met&lt;/i&gt; Inhibitors

Figure S2 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Figure S3 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation

NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China

MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature

Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study

Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer.

Abstract 6499: The landscape of MET exon 14 skipping mutations in non-small cell lung cancer patients identified by next-generation sequencing

Comprehensive analysis of <i>MET</i> mutations in NSCLC patients in a real-world setting

A robust and accurate method to detect MET Exon 14–skipping mutation in pan-cancer samples using an NGS-based RNAseq approach.

Plasma ddPCR for the detection of MET amplification in advanced NSCLC patients: a comparative real-world study

MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study

Figure S3 from Detection of <i>met</i> Polysomy by Next-generation Sequencing and Its Clinical Relevance for <i>met</i> Inhibitors

Figure S4 from Detection of <i>met</i> Polysomy by Next-generation Sequencing and Its Clinical Relevance for <i>met</i> Inhibitors

Table TS2 from Detection of <i>met</i> Polysomy by Next-generation Sequencing and Its Clinical Relevance for <i>met</i> Inhibitors